BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 14751928)

  • 21. Transcriptional activation is a key function encoded by MLL fusion partners.
    Zeisig BB; Schreiner S; García-Cuéllar MP; Slany RK
    Leukemia; 2003 Feb; 17(2):359-65. PubMed ID: 12592336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes.
    Corral J; Lavenir I; Impey H; Warren AJ; Forster A; Larson TA; Bell S; McKenzie AN; King G; Rabbitts TH
    Cell; 1996 Jun; 85(6):853-61. PubMed ID: 8681380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
    Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
    Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Turning on a dimer: new insights into MLL chimeras.
    Hsu K; Look AT
    Cancer Cell; 2003 Aug; 4(2):81-3. PubMed ID: 12957280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dimerization of MLL fusion proteins immortalizes hematopoietic cells.
    Martin ME; Milne TA; Bloyer S; Galoian K; Shen W; Gibbs D; Brock HW; Slany R; Hess JL
    Cancer Cell; 2003 Sep; 4(3):197-207. PubMed ID: 14522254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The leukemogenic fusion of MLL with ENL creates a novel transcriptional transactivator.
    Schreiner SA; García-Cuéllar MP; Fey GH; Slany RK
    Leukemia; 1999 Oct; 13(10):1525-33. PubMed ID: 10516753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
    Ayton PM; Cleary ML
    Genes Dev; 2003 Sep; 17(18):2298-307. PubMed ID: 12952893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.
    Armstrong SA; Staunton JE; Silverman LB; Pieters R; den Boer ML; Minden MD; Sallan SE; Lander ES; Golub TR; Korsmeyer SJ
    Nat Genet; 2002 Jan; 30(1):41-7. PubMed ID: 11731795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene.
    Zeleznik-Le NJ; Harden AM; Rowley JD
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10610-4. PubMed ID: 7938000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.
    Lavau C; Du C; Thirman M; Zeleznik-Le N
    EMBO J; 2000 Sep; 19(17):4655-64. PubMed ID: 10970858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.
    Drynan LF; Pannell R; Forster A; Chan NM; Cano F; Daser A; Rabbitts TH
    EMBO J; 2005 Sep; 24(17):3136-46. PubMed ID: 16096649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathogenesis of MLL-associated leukemias.
    Eguchi M; Eguchi-Ishimae M; Greaves M
    Int J Hematol; 2005 Jul; 82(1):9-20. PubMed ID: 16105754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene.
    Dobson CL; Warren AJ; Pannell R; Forster A; Rabbitts TH
    EMBO J; 2000 Mar; 19(5):843-51. PubMed ID: 10698926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
    Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
    PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein.
    Yam JW; Jin DY; So CW; Chan LC
    Blood; 2004 Feb; 103(4):1445-53. PubMed ID: 14551139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.
    Drexler HG; Quentmeier H; MacLeod RA
    Leukemia; 2004 Feb; 18(2):227-32. PubMed ID: 14671638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
    Ayton PM; Chen EH; Cleary ML
    Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.
    Maki K; Mitani K; Yamagata T; Kurokawa M; Kanda Y; Yazaki Y; Hirai H
    Blood; 1999 May; 93(10):3216-24. PubMed ID: 10233872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia.
    Fuchs U; Rehkamp G; Haas OA; Slany R; Kōnig M; Bojesen S; Bohle RM; Damm-Welk C; Ludwig WD; Harbott J; Borkhardt A
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8756-61. PubMed ID: 11438682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MLL: a histone methyltransferase disrupted in leukemia.
    Hess JL
    Trends Mol Med; 2004 Oct; 10(10):500-7. PubMed ID: 15464450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.